The Trump administration's Department of Justice issued a final order in late April 2026 rescheduling FDA-approved marijuana products and certain state-legal medical cannabis to Schedule III, easing tax burdens under Section 280E for compliant operators while leaving recreational marijuana in Schedule I. This partial reform, building on HHS's 2023 recommendation, prompted a new expedited DEA administrative hearing set for June 29 to July 15, 2026, to evaluate broader rescheduling. Yesterday, the House Appropriations Committee voted to block full rescheduling via a funding rider, signaling congressional resistance amid ongoing Farm Bill debates, though such measures often fail in final appropriations. Traders eye the hearing outcome and potential executive actions as pivotal.
Tóm tắt AI thử nghiệm tham chiếu dữ liệu Polymarket. Đây không phải tư vấn giao dịch và không ảnh hưởng đến cách thị trường này được giải quyết. · Cập nhật$758,445 KL.
Mar 31, 2026
June 30
3%
December 31
25%
$758,445 KL.
June 30
$337,068 KL.
3%
December 31
$156,494 KL.
25%
This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by June 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by March 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.The Trump administration's Department of Justice issued a final order in late April 2026 rescheduling FDA-approved marijuana products and certain state-legal medical cannabis to Schedule III, easing tax burdens under Section 280E for compliant operators while leaving recreational marijuana in Schedule I. This partial reform, building on HHS's 2023 recommendation, prompted a new expedited DEA administrative hearing set for June 29 to July 15, 2026, to evaluate broader rescheduling. Yesterday, the House Appropriations Committee voted to block full rescheduling via a funding rider, signaling congressional resistance amid ongoing Farm Bill debates, though such measures often fail in final appropriations. Traders eye the hearing outcome and potential executive actions as pivotal.
This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by June 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
Thị trường mở: Feb 7, 2026, 5:04 PM ET
Khối lượng
$758,445Ngày kết thúc
Mar 31, 2026Thị trường mở
Feb 7, 2026, 5:04 PM ETResolver
0x65070BE91...This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by June 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by March 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.The Trump administration's Department of Justice issued a final order in late April 2026 rescheduling FDA-approved marijuana products and certain state-legal medical cannabis to Schedule III, easing tax burdens under Section 280E for compliant operators while leaving recreational marijuana in Schedule I. This partial reform, building on HHS's 2023 recommendation, prompted a new expedited DEA administrative hearing set for June 29 to July 15, 2026, to evaluate broader rescheduling. Yesterday, the House Appropriations Committee voted to block full rescheduling via a funding rider, signaling congressional resistance amid ongoing Farm Bill debates, though such measures often fail in final appropriations. Traders eye the hearing outcome and potential executive actions as pivotal.
This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by June 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
Khối lượng
$758,445Ngày kết thúc
Mar 31, 2026Thị trường mở
Feb 7, 2026, 5:04 PM ETResolver
0x65070BE91...The Trump administration's Department of Justice issued a final order in late April 2026 rescheduling FDA-approved marijuana products and certain state-legal medical cannabis to Schedule III, easing tax burdens under Section 280E for compliant operators while leaving recreational marijuana in Schedule I. This partial reform, building on HHS's 2023 recommendation, prompted a new expedited DEA administrative hearing set for June 29 to July 15, 2026, to evaluate broader rescheduling. Yesterday, the House Appropriations Committee voted to block full rescheduling via a funding rider, signaling congressional resistance amid ongoing Farm Bill debates, though such measures often fail in final appropriations. Traders eye the hearing outcome and potential executive actions as pivotal.
Tóm tắt AI thử nghiệm tham chiếu dữ liệu Polymarket. Đây không phải tư vấn giao dịch và không ảnh hưởng đến cách thị trường này được giải quyết. · Cập nhật
Cẩn thận với liên kết bên ngoài.
Cẩn thận với liên kết bên ngoài.
Câu hỏi thường gặp